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Abstract 
We investigated the role of bone morphogenetic proteins (BMPs) in suppression of all-trans 
retinoic acid (ATRA)-mediated differentiation of leukemic promyelocytes. In NB4 and HL60 cell 
lines, BMPs reduced the percentage of differentiated cells, and suppressed PU.1 and C/EBPε 
gene expression induced by ATRA. BMP and ATRA synergized in the induction of ID genes, 
causing suppression of differentiation. In primary acute promyelocytic leukemia bone-marrow 
samples, positive correlation of PML/RARα and negative of RARα with the expression of BMP-
4, BMP-6 and ID genes were found. We concluded that BMPs may have oncogenic properties 
and mediate ATRA resistance by a mechanism that involves ID genes. 
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Introduction 
 
Acute promyelocytic leukemia (APL) is characterized by the accumulation of abnormal 
promyelocytes unable to differentiate into granulocytes and specific translocation 
t(15;17)(q22;q21) [1, 2]. Translocation results in the formation of PML/RARα (promyelocytic 
leukemia/retinoic acid receptor α) fusion gene that plays a central role in leukemogenesis of APL 
by blocking the function of RARα and PML proteins responsible for differentiation and apoptosis 
of APL cells [3]. All-trans retinoic acid (ATRA) is used for treatment of APL patients with high 
rate of complete remission when used alone or in combination with standard cytotoxic treatment 
[4]. Retinoic acid (RA) acts as morphogen through two subfamilies of nuclear receptors (RAR 
and RXR), ligand inducible transcription factors, in order to regulate the expression of genes 
containing retinoid response elements [5]. ATRA has been shown to induce terminal 
differentiation of APL cells by activation of RARα, and by inducing degradation of PML/RARα 
[2]. However, prolonged ATRA treatment often results in relapse due to the development of 
ATRA resistance by leukemic cells [4]. Although early studies suggested that an adaptive 
hypercatabolic response to pharmacological doses of ATRA is the principal mechanism of 
resistance, recent observations suggest that molecular disturbances in APL cells have a 
predominant role [6].  
Bone morphogenetic proteins (BMPs) are multi-functional growth factors that belong to the 
transforming growth factor β (TGF-β) superfamily. Besides their role in bone physiology, they 
also regulate proliferation, differentiation, morphogenesis and apoptosis of hematopoietic cells. 
BMP-2 can induce hematopoietic environment after subcutaneous implantation and regulate 
apoptosis in various B-cell lines and primary myeloma cells [7-9]. BMP-4 has a crucial 
instructive role for the induction and formation of blood cell precursors [10] and induces 
formation of embryonic hematopoietic tissues [11]. BMP-6, produced by bone-marrow (BM) 
cells, participates in the regulation of proliferation, apoptosis and differentiation of B-cell lineage 
[12]. Dosen-Dahl et al showed that treatment with TGF-β or BMP-6 protects leukemic cells 
against chemotherapy-induced cell death and allow them to escape therapy [13]. 
BMPs are known to exert their effect through two different types of serine-threonine kinase 
receptors known as receptors type I (BMP receptor (BMPR)IA, BMPRIB and activin receptor 
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(ActR)IA) and type 2 (BMPRII, ActRIIA and ActRIIB), and intracellular SMAD (small mothers 
against decapentaplegic) proteins, which play a central role in BMP signaling [14]. Important 
direct target of SMAD pathway is the gene family of DNA binding inhibitors (ID) [15]. ID genes 
encode a family of proteins that block basic helix-loop-helix transcription factors to bind to 
DNA, thus interrupting their regulatory role in many developmental and differentiation processes. 
Different studies on human tumors proved their oncogenic properties in regulating cell-cycle 
progression, migration and invasiveness [15-19].  
Our previous study has shown that BMP-2, BMP-4 and BMP-7, and their receptors were strongly 
expressed in patients with APL, paralleled by the expression of PML/RARα oncogene. Absence 
of BMP expression correlated with clearance of the tumor molecular marker [20]. In this study, 
we aimed to investigate molecular mechanisms by which BMPs suppress differentiation of APL 
cells induced by ATRA, using myeloid cell lines NB4 and HL60, and primary samples from APL 
patients. Since RA/RAR pathway functionally interacts with BMP/SMAD signaling [21], we 
proposed that BMP signal interfere with ATRA-induced differentiation of APL cells. Our 
findings may add to the understanding of the mechanisms of resistance to ATRA in APL patients. 
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Materials and methods 
Patient samples and cell lines 
Human myeloid leukemia cell lines NB4 and HL60 (DSMZ cell line collection, Braunschweig, 
Germany) were grown in RPMI 1640 with 10% fetal calf serum (FCS) (Gibco, Invitrogen Ltd., 
Grand Island, NY, USA), 2 mM glutamax and 100 U/ml penicillin/streptomycin, in a 5% CO2 at 
37ºC. APL cell line NB4 carries the specific t(15;17) translocation, whereas HL60, a 
myeloblastic leukemia cell line, lacks t(15;17) translocation but differentiates along granulocytic 
pathway upon ATRA treatment. To induce differentiation, cells (0.3×106/mL in 25 cm2 flasks) 
were treated
 
with ATRA (0.5 µM for NB4 and 2 µM for HL60). Recombinant human (rh)BMP-2, 
rhBMP-4 or rhBMP-6 (all from R&D Systems, Abingdon, UK), and soluble BMP antagonist 
NOGGIN (NOG) (PeproTech, London, UK) were added as indicated in each experiment.  
After obtaining approval from the institutional Ethics Committee and informed consent from 
participants, we analyzed BM and peripheral blood (PBL) samples from 5 APL patients collected 
as a part of routine clinical assessment, at diagnosis and during the clinical follow-up. BM 
specimens were obtained by sterile punction of the iliac crest. PBL was drawn by standard 
venipuncture, followed by mononuclear cell separation using Histopaque (Sigma, St. Louis, MO, 
USA; density 1.077 g/ml). Diagnosis was established by morphological characterization, 
cytochemistry, and cytogenetic- and immuno-phenotyping according to the criteria of French-
American-British classification for AML-M3 [22]. Presence of PML/RARα fusion gene as a 
tumor molecular marker was confirmed by polymerase chain reaction (PCR) analysis. Patients 
were treated with the combination of oral ATRA (45 mg/m2 per day), divided into 2 doses, and 
idarubicin (12 mg/m
2
 on days 2, 4, 6 and 8) as described previously [20]. 
 
May-Grünwald Giemsa staining 
Cytospin preparations for standard May-Grünwald Giemsa staining were made after ATRA 
treatment, as indicated in each experiment, to detect morphological changes associated with 
granulocyte differentiation (pale cytoplasm and mulitlobulated segmented nucleus) [23].  
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Flow-cytometric analysis 
Myeloid leukemia cell lines NB4 and HL60 were analyzed by flow cytometry using a FACS 
Calibur instrument and Cell-Quest software (BD Biosciences, San Jose, CA, USA). Cells were 
analyzed for the phenotypic evidence of differentiation (expression of granulocyte surface 
markers CD11b and CD11c) by standard protocols [24]. Viability and apoptosis were evaluated 
by annexin V/propidium iodide (PI) staining (BD Biosciences) according to the manufacturer’s 
instructions. Cells were classified on dot-plots as dead (PI
+
), apoptotic (PI
−
/annexin V
+
) or viable 
(double negative). For cell-cycle analyses, cells were resuspended in DNA staining solution (0.01 
M Tris, 10 mM NaCl, 700 U/L RNAse, 7.5 × 10
-5
 M PI, 0.01% Nonidet P-40). Cell-cycle 
distribution was presented as histograms (G0/G1, S, G2/M phases) [8]. 
 
Gene expression analysis 
Total RNA was extracted (TriPure; Roche Mannheim, Germany) from primary APL BM and 
PBL samples, or NB4 and HL60 cells, reversely transcribed to cDNA (MuLV Reverse 
Transcriptase; Applied Biosystems, Foster City, CA) and amplified by quantitative (q)PCR using 
specific TaqMan assays (Supplementary table 1) in an ABI Prism 7000 Sequence Detection 
system (Applied Biosystems). Each reaction was performed in triplicate in a 25 µL reaction 
volume as previously described [8]. The relative quantities of unknown samples for the each gene 
were interpolated from the six-point serial dilution standard curve of the calibrator sample (BM 
cells or cell lines). To equalize samples according to the amount of input cDNA, the relative 
quantity of the target gene was normalized to glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) as the endogenous control. 
 
Statistics 
All experiments were repeated at least three times. Gene expression triplicates in treated cell lines 
were expressed as mean ± standard deviation (SD) and compared using analysis of variance with 
Student-Newman-Keuls posthoc test. Gene expressions in primary samples were correlated to 
clinical data using rank correlation and Spearman’s coefficient of rank correlation rho (ρ) with its 
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95% confidence interval. Statistical analysis was performed using MedCalc software-package 
(Mariakerke, Belgium). For all experiments, α-level was set at 0.05.
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Results 
ATRA induced differentiation of NB4 and HL60 cell lines  
We confirmed ATRA-induced differentiation of myeloid leukemia cell lines NB4 and HL60 by 
the expression of differentiation makers (CD11b/CD11c), and changes in cell proliferation and 
apoptosis. Differentiation was followed up to 4 days, with increase in the expression of CD11b 
and CD11c in both cell lines with the time of ATRA treatment (Figure 1A). Differentiated cells 
showed morphological changes characteristic for granulocytic differentiation, containing pale 
cytoplasm and multilobulated segmented nucleus (Figure 1A). At the representative time-point 
(day 3 of ATRA treatment for NB4 and day 4 for HL60, according to the percent of 
CD11b/CD11c-positive cells), we observed the suppression of cell-cycle progression (Figure 
1B). Furthermore, ATRA decreased the percentage of apoptotic NB4 cells, but increased the 
percentage of apoptotic HL60 cells, indicating that proapoptotic effect is not associated with 
t(15;17) rearrangement [25]. Finally, we determined the expression of PML/RARα oncogene in 
NB4 cells by qPCR, which was further increased by ATRA treatment together with the 
expression of total RARα (Figure 1C). We also confirmed the responsiveness of cell lines to 
BMPs by detecting gene expression for BMP receptors (ActRIA, BMPRIA, BMPRIB, BMPRII, 
ActRIIA, ActRIIB), BMP-signaling related molecules (SMAD5, SMAD6, NOG, bone 
morphogenetic and activin membrane-bound inhibitor (BAMBI)) and BMP-target genes (ID1, 
ID2, cKit), with and without ATRA treatment (Figure 1C). The major difference between two 
analyzed cell lines, that could influence the functional response of those cells to BMP treatment, 
is huge induction of ID genes particularly in NB4 cells by ATRA and constitutively lower 
expression of cKit in HL60 cells.  
 
BMPs suppressed differentiation of ATRA-treated NB4 and HL60 cell lines 
Since our previous study on APL primary BM samples showed that treatment with ATRA was 
associated with the suppression of BMP expression [20], we aimed to reveal the effect of BMPs 
on ATRA induced differentiation of NB4 cells as an in vitro model for APL. HL60 cell line, not 
bearing the specific t(15;17)(q22;q21) translocation, was used in addition to test if the BMP 
effect is PML/RARα specific. Cells were treated with the combination of ATRA and BMP-2, 
BMP-4 or BMP-6. BMP alone did not affect the expression of differentiation markers, but in 
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combination with ATRA reduced the percent of cells expressing CD11b and CD11c by 40 to 
60% respectively, with stronger effect in NB4 cells (Figure 2A). This effect was paralleled by 
expected morphological findings, i.e. more immature cell features upon combined treatment with 
BMP and ATRA compared to ATRA alone.  
Our further aim was to evaluate BMP effect by analyzing the expression pattern of several 
intracellular molecules involved in proliferation, differentiation and apoptosis of APL cells. 
Genes for ankyrin repeat and SOCS box protein 2 (Asb2) involved in RA-induced growth 
inhibition and myeloid differentiation, myeloid-specific transcription factors PU.1 and CCAAT-
enhancer-binding proteins ε (C/EBPε), and ubiquitin-conjugating enzyme UBE2D3 [26, 27] were 
up-regulated in ATRA-treated groups in both cell lines. Expression of proto-oncogene Bcl-2, 
tyrosine-protein kinase cKit and distal-less homeobox gene 4 (Dlx4) associated with cell 
proliferation and tumorigenesis [28], were decreased by ATRA treatment (Figure 2B). In general, 
BMPs more effectively suppressed genes associated with cell differentiation, specifically PU.1, 
UBE2D3 and C/EBPε in NB4 cell line, compared with very weak or negligible effect on the 
restoration of proliferative/antiapoptotic oncogene expression.  
 
Effect of BMP-2 and Noggin on promyelocytic cell lines treated with ATRA 
Since we did not find significant difference in the effectiveness between tested BMPs, we 
assumed that their action was mediated by the same receptor complex (possible BMPRIA in 
combination with BMPRII or ActRIIB, according to the expression pattern presented at Figure 
1C). Therefore we used BMP-2 as a model to further study the role of BMPs in ATRA-
resistance. Again we confirmed that BMP-2 suppressed NB4 and HL60 ATRA-induced 
differentiation, assessed by CD11b/CD11c expression, but also revealed that the effect was BMP-
specific since we were able to reverse BMP-mediated suppression of differentiation by NOG 
pretreatment (Figure 3A).  
Further on, we aimed to identify molecular cross-road between BMP-signaling pathway and 
induction of genes that regulate promyelocyte differentiation. ID genes are well documented 
direct targets of BMP signaling [29], which, at the same time, have important role in granulocyte 
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differentiation [30] as well as malignant transformation in several cell types [15]. ID1 and ID2 
genes were induced by BMP-2 in both tested cell lines, but up-regulated by ATRA treatment only 
in NB4 cells. Combined treatment with BMP-2 and ATRA synergistically enhanced ID genes, 
particularly ID1 in both cell lines (Figure 3B). In addition, we hypothesized that more 
pronounced differentiation-suppressive effect of BMPs seen in NB4 cells compared with HL60 
(approximately 50% suppression of CD11b expression in NB4 compared with 30% in HL60 
cells, Figure 3A) could be explained by constitutively higher expression of cKit, transcriptional 
target of BMPs with a role in hematopoietic cell survival and proliferation [31]. Nevertheless, 
cKit expression was highly suppressed by ATRA treatment, and not significantly affected by 
BMP-2. Combined treatment was able to only weakly increase the expression compared to 
ATRA alone (Figure 3B). 
 
Correlation of PML/RARa oncogene expression and BMP-related molecules in APL patients 
To translate the importance of the obtained findings to clinical setting, we collected the follow-up 
BM and PBL samples of 5 APL patients and assessed the expression of BMP-related genes in 
correlation with the disease molecular marker (Figure 4). The patients were included at the time 
of diagnosis, with detectable expression of PML/RARα oncogene in BM and PBL. Patients 
showed prolonged molecular remission with ATRA treatment, except for patient #1, who died 
upon relapse and disease complications. In parallel, expression of total RARα was assessed, 
showing reciprocal expression profile compared with the fusion oncogene PML/RARα (ρ=-
0.430, 95% CI -0.692 to -0.068, p=0.025).  
Based on the expression pattern of BMP-related molecules, we further analyzed their correlations 
(specifically BMP-2, -4, -6, ID1, ID2, cKit, BAMBI, NOG, PU.1, UBE2D3, C/EBPε) with 
PML/RARα and RARα (Table 1). The most significant positive correlations were found for 
PML/RARα and BMPs as well as their transcription target ID1, whereas significant negative 
correlations were found for BMP antagonist BAMBI and transcription factor PU.1, with the 
reciprocal correlations for RARα (Table 1). Finally, expression of cKit [32] was in negative 
correlation with PML/RARα and positive with RARα. 
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Discussion 
We studied mechanisms by which BMPs affect response of APL cells to ATRA treatment and 
found ID genes as a possible molecular link between BMP signaling and suppression of myeloid 
differentiation. Previous studies showed that ID genes were induced by ATRA in NB4 cells and 
APL patients [33], and by BMP-4 in embryonic stem cells and a range of cell lines [34], but this 
is the first report of the synergistic enhancement of ID genes by combined treatment with BMPs 
and ATRA. Addition of BMP antagonist NOG to ATRA/BMP-2 treatment suppressed ID1 and 
ID2 expression, which is consistent with the observed inhibition of SMAD1/5/8 phosphorylation 
and ID protein up-regulation upon treatment with BMP-2 and NOG [35]. Moreover, in primary 
APL BM samples we found positive correlation of PML/RARα and negative of RARα with ID 
genes as well as their upstream activators BMP-4 and BMP-6.  
To better characterize the effect of BMPs on differentiation of APL cells, we used NB4 and 
HL60 cell lines. NB4 is RA sensitive APL cell line that harbors the specific t(15;17) 
translocation. HL60, on the other hand, is a myeloblastic leukemia cell line that responds to RA 
but lacks t(15;17) translocation, suggesting that genetic alterations distinct from translocation 
involving RARα might generate APL-like phenotype [36]. In NB4 cells ATRA enhanced the 
expression of oncogene PML/RARα and total RARα, restoring RA-modulated myeloid 
differentiation [2, 37]. In parallel, ATRA reduced apoptotic/dead population of NB4 cells, which 
may be related to APL-differentiation syndrome seen upon ATRA treatment [38]. Syndrome is 
caused by the accumulation of mature granulocytes and can lead to a fatal outcome in APL 
patients. Increase in the percentage of cells in G0/G1 cell-cycle phase is known to be caused by 
ATRA-induced over expression of ID1 and ID2 [33]. Among tested BMPs, NB4 expressed 
exclusively BMP-2 and HL60 BMP-4 (not shown), which act through the same receptor 
complexes, and both lines expressed BMP receptors, specifically BMPRIA, BMPRII and 
ActRIIB. BMPs and their receptors has been detected in BM in different pathological conditions 
[7, 8, 20], suggesting an autocrine action. 
BMP signaling pathway plays an important role in regulation of hematopoietic niches and stem 
cell population size maintaining BM homeostasis [39] as well as differentiation and growth of 
leukemic cells [9, 10, 12]. Therefore we proposed that BMP signal may target genes important 
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for granulocyte differentiation, causing promyelocyte resistance to ATRA. Several genes were 
identified to be rapidly induced by ATRA, i.e. SOCS box family gene Asb2, due to binding of 
RARα to Asb2 promoter [26], and hematopoietic transcription factor PU.1, found to be 
suppressed in APL cell lines [27]. PU.1 shares some transcription targets with BMPs, such as ID2 
[40], and interacts with SMAD1 to enhance macrophage expression of interleukin 1β after BMP-
6 treatment [41]. ATRA induction of PU.1 in cells harboring PML/RARα is mediated by up-
regulation of the C/EBP proteins, important for terminal granulocytic differentiation [27]. We 
observed that both PU.1 and C/EBPε were increased after treatment with ATRA, and repressed 
by BMPs, indicating that this could be one of the mechanisms involved in resistance to ATRA-
induced differentiation [42]. C/EBP transcription factors interact with SMAD proteins leading to 
formation of C/EBP-SMAD complexes. Possible mechanism of C/EBP-SMAD antagonism could 
be the interference with C/EBP coactivator or competition for a common coactivator [43]. On the 
other hand BMPs could not restore the expression of proliferative genes highly suppressed by 
ATRA, including oncogene Bcl-2 and homebox gene Dlx4 [28, 44, 45]. Nevertheless, expression 
of cyclin D1 degradation enzyme UBE2D3, important for ATRA-mediated cell growth arrest 
[46], was down regulated by addition of BMPs, possible causing an increase in the proportion of 
cells in the active cell-cycle phases (not shown).  
Since it has been shown that SMAD3 interacts with RARα in a TGF-β dependent manner [47], 
we proposed that simultaneous activation by ATRA and BMPs causes those two signals to 
interfere perpetuating immature APL phenotype. BMP signal during ATRA treatment synergizes 
in the induction of ID genes, which may lead to inhibition of differentiation and propose BMPs 
as oncogenic proteins. Despite the role in granulocyte differentiation, ID genes promote cell 
proliferation and malignant transformation in different cell types including hematopoietic cells, 
particularly myeloid [48]. cKit has also been involved in RA as well as BMP action [49, 50]. It 
has an important role in proliferation, differentiation and survival of normal hematopoietic and 
leukemic cells [49, 50]. We found negative correlation of cKit with oncogene PML/RARα and 
positive with RARα in APL BM samples, indicating its role in differentiation of APL cells upon 
ATRA treatment rather than proto-oncogenic property [32].  
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Finally, we confirmed the importance of BMPs and ID genes in the pathogenesis of APL by 
observing positive correlation between their expressions with the fusion oncogene PML/RARα in 
BM of APL patients. Molecular remission and enhanced expression of total RARα, able to 
restore RA-mediated differentiation, was paralleled by the suppression of those genes, suggesting 
that BMPs play important role in resistance to ATRA often seen in APL patients. It has been 
shown that RA promotes degradation of phosphorylated SMAD1 reducing BMP signal [21], but 
in our study ATRA decreased expression of BMP antagonists NOG and BAMBI, and inhibitory 
SMAD6, which would have the opposite effect. This suggests BMP antagonists as possible 
complementary therapeutic strategy for ATRA-resistant patients. 
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Figure legends: 
Figure 1. Effect of all-trans retinoic acid (ATRA) treatment on differentiation of NB4 and 
HL60 cell lines. A) Cell lines were treated with ATRA (NB4 0.5 µM, left panel; HL60 2 µM, 
right panel) and analyzed at several time-points (day 1 to day 4) for the morphological 
changes characteristic for granulocyte differentiation (standard May-Grünwald Giemsa 
staining, magnification 1000×, under immersion oil) and cell surface phenotype markers 
(CD11b/CD11c by flow cytometry) compared to ATRA-non treated control (ctrl). B) Effect 
of ATRA on the surface phenotype (expression of CD11b/CD11c), cell cycle distribution 
(G0/G1, S, G2/M phases) and apoptosis (percentage of dead/apoptotic cells by Annexin V/PI 
staining) was further analyzed at the representative time-point (day 3 of ATRA tretment for 
NB4, left panel; day 4 for HL60, right panel) by flow cytometry. C) Expression of acute 
promyelocytic leukemia (APL) molecular markers (promyelocytic leukemia/retinoic acid 
receptor α (PML/RARα) fusion oncogene and total RARα receptor), bone morphogenetic 
protein (BMP) receptors (activin receptor (ActR)IA, BMP receptor (BMPR)IA, BMPRIB, 
BMPRII, ActRIIA, ActRIIB), and BMP-related molecules (inhibitors of DNA binding (ID)1, 
ID2, tyrosine-protein kinase cKit, small mothers against decapentaplegic (SMAD)5, SMAD6, 
NOGGIN (NOG), and bone morphogenetic and activin membrane-bound inhibitor (BAMBI)) 
in NB4 and HL60 cell lines (day 2 of ATRA tretment for NB4 and day 3 for HL60). RNA 
was extracted from leukemia cell lines NB4 and HL60 and analyzed by quantitative PCR. 
Expression of target genes was presented as RNA relative quantity and normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the endogenous control. Data are 
representative of three similar experiments. 
 
  
 
Figure 2. Effect of bone morphogenetic protein (BMP)-2, BMP-4 and BMP-6 on all-trans 
retinoic acid (ATRA)-induced differentiation of NB4 and HL60 cell lines. Cell lines were 
treated by ATRA (NB4 0.5 µM, left panel; HL60 2 µM, right panel) and BMP-2, BMP-4 or 
BMP-6 (25 ng/mL for all), and assessed at day 2 of ATRA treatment for NB4 and day 3 for 
HL60. A) Cells were analyzed for morphological changes of differentiation (standard May-
Grünwald Giemsa staining, magnification 1000×, under immersion oil) and cell surface 
phenotype (expression of CD11b/CD11c by flow cytometry) compared to non-treated cells 
(ctrl). B) Expression of genes affected by ATRA-induced differentiation (ankyrin repeat and 
SOCS box protein 2 (Asb2), transcription factor PU.1, CCAAT-enhancer-binding-proteins 
(C/EBP)ε and C/EBPα, ubiquitin-conjugating enzyme (UBE)2D3), tyrosine-protein kinase 
cKit, apoptotic regulator B-cell lymphoma (Bcl)-2, and distal-less homebox (Dlx)4) in NB4 
and HL60 cell line. RNA was extracted from myeloid leukemia cell lines NB4 and HL60 after 
treatment with ATRA and BMPs, and analyzed by quantitative PCR. Expression of target 
genes was presented as RNA relative quantity and normalized to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as the endogenous control. Data are representative of three similar 
experiments. 
 
 
Figure 3. Effect of bone morphogenetic protein (BMP)-2 and NOGGIN (NOG) on NB4 and 
HL60 cells treated with all-trans retinoic acid (ATRA). Cell lines were treated with different 
combinations of ATRA (NB4 0.5 µM, left panel; HL60 2 µM, right panel), BMP-2 (25 
ng/mL) and NOG (100 ng/mL). A) Cells were analyzed for cell surface phenotype markers 
(CD11b/CD11c) by flow cytometry, at day 1 of ATRA treatment for NB4 and day 2 for 
HL60, in non-treated (ctrl) and treated samples (ATRA, BMP-2, ATRA+BMP-2 and 
ATRA+BMP-2/NOG). Data are representative of three similar experiments. B) Expression of 
inhibitors of DNA binding (ID)1, ID2 in NB4 and HL60 cell lines and tyrosine-protein kinase 
cKit in NB4 cell line. RNA was extracted from leukemia cell lines NB4 and HL60 after 12 
hours or 24 hours of treatment, respectively, and analyzed by quantitative PCR. Expression of 
target genes was presented as RNA relative quantity and normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as the endogenous control. Data were presented as 
triplicate mean ± standard deviation (SD) and analyzed using analysis of variance with 
Student-Newman-Keuls posthoc test; p ≤ 0.05 were considered statistically significant. *, 
indicates statistically significant difference compared to BMP-2 or ATRA alone; **, indicates 
statistically significant difference compared to combined ATRA/BMP-2 treatment. 
 
  
 
Figure 4. Five patients with the diagnosis of acute promyelocytic leukemia before and after 
the combined cytostatic/all-trans retinoic acid (ATRA) treatment. Bone-marrow (BM) and 
peripheral blood (PBL) samples were collected from patients at the time of diagnosis (the first 
presented time-point in all patients) and at clinical follow-up time-points during ATRA 
treatment (7 time points for patient #1, 5 for #2, 2 for #3, 6 for #4 and 3 for #5). Diagnosis 
was established according to French-American-British classification for AML-M3. A) 
Expression pattern of bone morphogenetic protein (BMP)-2, BMP-4 and BMP-6, and BMP-
related genes (bone morphogenetic and activin membrane-bound inhibitor (BAMBI), BMP 
antagonist NOGGIN (NOG), inhibitors of DNA binding (ID)1, ID2, tyrosine-protein kinase 
cKit, transcription factor PU.1, ubiquitin-conjugating enzyme (UBE)2D3, CCAAT-enhancer-
binding-proteins (C/EBP)ε) was analyzed in BM samples by quantitative (q)PCR. B) The 
expression of fusion oncogene promyelocytic leukemia/retinoic acid receptor α (PML/RARα) 
and total RARα was verified in BM and PBL at corresponding time-points by qPCR. 
Expression of target genes was presented as RNA relative quantity and normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the endogenous control. nd, not 
determined. 
 
 
Table 1. Correlation of the expression of BMPs and BMP-related genes with the disease 
molecular marker PML/RARα and total RARα receptor 
 
* Correlations between gene expression of fusion promyelocytic leukemia/retinoic acid receptor α (PML/RARα) 
or total RARα receptor with bone morphogenetic proteins (BMP) and BMP-related genes (inhibitors of DNA 
binding (ID)1, ID2, cKit, NOGGIN, bone morphogenetic and activin membrane-bound inhibitor (BAMBI), 
transcription factor PU.1, CCAAT-enhancer- binding-proteins (C/EBP)ε and ubiquitin-conjugating enzyme 
(UBE)2D3) in bone-marrow samples of acute promyelocytic leukemia patients analyzed by quantitative PCR. 
** Gene expression values were analyzed using rank correlation and Spearman’s coefficient of rank correlation 
rho (ρ) with its 95% confidence interval (CI). Significant correlations (p≤0.05) are presented in bold. 
PML/RARα vs* Spearmans rho (95% CI), p** RARα vs Spearmans rho (95% CI), p 
BMP-2 -0.17 (-0.51 to 0.22), p=0.385 BMP-2 0.01 (-0.36 to 0.38), p=0.952 
BMP-4 0.82 (0.65 to 0.91), p<0.001 BMP-4 -0.22 (-0.55 to 0.17), p=0.252 
BMP-6 0.51 (0.16 to 0.74), p=0.010 BMP-6 -0.48 (-0.72 to -0.12), p=0.015 
ID1 0.46 (0.06 to 0.73), p=0.029 ID1 -0.10 (-0.48 to 0.32), p=0.642 
ID2 0.29 (-0.13 to 0.62), p=0.160 ID2 -0.34 (-0.65 to 0.08), p=0.106 
cKit -0.49 (-0.73 to -0.15), p=0.011 cKit 0.43 (0.07 to 0.69), p=0.025 
BAMBI -0.55 (-0.77 to -0.23), p=0.004 BAMBI 0.69 (0.42 to 0.84), p<0.001 
NOGGIN 0.16 (0.22 to 0.51), p=0.398 NOGGIN 0.07 (-0.31 to 0.43), p=0.716 
PU.1 -0.68 (-0.84 to -0.41), p<0.001 PU.1 0.68 (0.42 to 0.84), p<0.001 
UBE2D3 -0.14 (-0.49 to 0.25), p=0.474 UBE2D3 -0.33 (-0.63 to 0.05), p=0.088 
C/EBPε -0.14 (-0.48 to 0.25), p=0.481 C/EBPε 0.01 (-0.37 to 0.38), p=0.975 
Supplementary table 1. TaqMan assays used for quantitative PCR analysis 
Gene* Gene symbol Assay ID 
PML/RARα PML-RARA fusion Hs03024794_ft 
RARα RARA Hs00940446_m1 
BMP-2 BMP2 Hs00154192_m1 
BMP-4 BMP4 Hs00370078_m1 
BMP-6 BMP6 Hs00233470_m1 
ActRIA ACVR1 Hs00153836_m1 
BMPRIA BMPR1A Hs01034910_g1 
BMPRIB BMPR1B Hs00176144_m1 
BMPRII BMPR2 Hs00176148_m1 
ActRIIA ACVR2A Hs00155658_m1 
ActRIIB ACVR2B Hs00609603_m1 
ID1 ID1 Hs03676575_s1 
ID2 ID2 Hs00747379_m1 
cKit KIT Hs00174029_m1 
SMAD5 SMAD5 Hs01557453_mH 
SMAD6 SMAD6 Hs00178579_m1 
NOGGIN NOG Hs00271352_s1 
BAMBI BAMBI Hs00180818_m1 
Asb2 ASB2 Hs00387867_m1 
PU.1 SPI1 Hs00231368_m1 
UBE2D3 UBE2D3 Hs00701790_s1 
C/EBPε CEBPE Hs00357657_m1 
C/EBPα CEBPA Hs00269972_s1 
Dlx4 DLX4 Hs00231080_m1 
Bcl-2 BCL2 Hs00153350_m1 
GAPDH GAPDH Hs99999905_m1 
* Assays used for quantitative PCR analysis were commercially available and used in accord to the manufacturer 
recommendations (Applied Biosystems). 
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